Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 9/20 | 0.60 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.59 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.59 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.59 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.59 |
| ▸ | GSK3A | P49840 | 2/20 | 0.59 |
| ▸ | GSK3B | P49841 | 2/20 | 0.59 |
| ▸ | CSNK1G2 | P78368 | 2/20 | 0.59 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.59 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.59 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.59 |
| ▸ | CSNK1G1 | Q9HCP0 | 2/20 | 0.59 |
| ▸ | CSNK1G3 | Q9Y6M4 | 2/20 | 0.59 |
| ▸ | CDK2 | P24941 | 1/20 | 0.59 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.59 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.59 |
| ▸ | RAF1 | P04049 | 6/20 | 0.49 |
| ▸ | CLK2 | P49760 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12024241 | 0.91 | BRAF (0.68) | BRAFPRKD3MAP4K4MAPK1MAPK8 | |
| SCHEMBL12024058 | 0.90 | BRAF (0.61) | BRAFPRKD3MAP4K4MAPK1MAPK8 | |
| SCHEMBL3816824 | 0.89 | BRAF (0.54) | BRAFPRKD3MAP4K4MAPK1MAPK8 | |
| SCHEMBL3808892 | 0.89 | MAPK8 (0.73) | BRAFPRKD3MAP4K4MAPK1MAPK8 | |
| SCHEMBL12024140 | 0.89 | BRAF (0.53) | BRAFPRKD3MAP4K4MAPK1MAPK8 | |
| SCHEMBL3813139 | 0.86 | BRAF (0.65) | BRAFPRKD3MAP4K4MAPK1MAPK8 | |
| SCHEMBL3808577 | 0.86 | PRKD3 (0.80) | BRAFPRKD3MAP4K4MAPK1MAPK8 | |
| SCHEMBL3526576 | 0.85 | PRKD3 (0.58) | BRAFPRKD3MAP4K4MAPK1MAPK8 | |
| SCHEMBL3477886 | 0.85 | BRAF (0.61) | BRAFPRKD3MAP4K4MAPK1MAPK8 | |
| SCHEMBL3810706 | 0.85 | BRAF (0.63) | BRAFPRKD3MAP4K4MAPK1MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301160-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301160-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301160-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| EP-1633758-B1 | IMIDAZOTHIAZOLES AND IMIDAZOXAZOLE DERIVATIVES AS INHIBITORS OF P38 | ARQULE INC (US) | 2011-11-23 | — | — | EP | disclosed |
| EP-1633758-B1 | IMIDAZOTHIAZOLES AND IMIDAZOXAZOLE DERIVATIVES AS INHIBITORS OF P38 | ARQULE INC (US) | 2011-11-23 | — | — | EP | disclosed |
| US-7902192-B2 | Inhibitors of P38 and methods of using the same | ARQULE, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902192-B2 | Inhibitors of P38 and methods of using the same | ARQULE, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902192-B2 | Inhibitors of P38 and methods of using the same | ARQULE, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| EP-2251343-A1 | IMIDAZOTHIAZOLES AS P38-KINASE-INHIBITORS | ARQULE, INC. (US) | 2010-11-17 | — | — | EP | disclosed |
| EP-2251343-A1 | IMIDAZOTHIAZOLES AS P38-KINASE-INHIBITORS | ARQULE, INC. (US) | 2010-11-17 | — | — | EP | disclosed |
| US-20070270418-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. | 2007-11-22 | — | — | US | disclosed |
| US-20070270418-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. | 2007-11-22 | — | — | US | disclosed |
| US-20070270418-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. | 2007-11-22 | — | — | US | disclosed |
| EP-1633758-A2 | IMIDAZOTHIAZOLES AND IMIDAZOXAZOLE DERIVATIVES AS INHIBITORS OF P38 | ARQULE, INC. (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004110990-A2 | IMIDAZOTHIAZOLES AND IMIDAZOXAZOLE DERIVATIVES AS INHIBITORS OF P38 | ARQULE, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270418-A1 | Inhibitors of P38 and Methods of Using the Same | MAPK1, MAPK8, MAPK7 | BRAF 179/4885PRKD3 541/4885MAP4K4 44/4885 |
| US-20110301160-A1 | Inhibitors of P38 and Methods of Using the Same | MAPK1, MAPK7, MAPK8 | BRAF 154/4885PRKD3 507/4885MAP4K4 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.